You are here

  • Home
  • Archive
  • Volume 11, Issue 1
  • Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

 

Online download statistics by month:

Online download statistics by month: January 2023 to September 2025

AbstractFullPdf
Jan 2023725734272
Feb 202320320385
Mar 202315715963
Apr 202311611638
May 202311111136
Jun 2023878723
Jul 202312012240
Aug 202311811818
Sep 2023858527
Oct 2023797938
Nov 202310610670
Dec 202310710841
Jan 2024939474
Feb 2024575740
Mar 2024818168
Apr 2024626344
May 2024666746
Jun 2024626136
Jul 2024929342
Aug 2024464527
Sep 2024494936
Oct 2024676752
Nov 2024495029
Dec 2024555633
Jan 2025474733
Feb 202512813022
Mar 2025636342
Apr 2025686842
May 2025555639
Jun 2025323241
Jul 2025110
Sep 2025770
Total319432151497